New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
09:15 EDTQCORQuestcor continues lower as FDA says reviewing Acthar lab test results
Shares of Questcor (QCOR) are down 3.8% in pre-market trading to $64.90 after falling 9% yesterday following Citron Research claiming the company's Acthar drug faces "severe risk" of being pulled from the market by the FDA. Following the Citron report, the FDA stated in an e-mail to Bloomberg that it had received a letter and lab results from an attorney as mentioned by Citron and was reviewing the materials. Questcor's COO Steve Cartt stated in an e-mail to Bloomberg First Word that "each Acthar lot meets FDA-mandated specifications which have not changed over several decades," the news service reported.
News For QCOR From The Last 14 Days
Check below for free stories on QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for QCOR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use